{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:10Z","timestamp":1772119390891,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"Osaka University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Single-agent chemotherapy with or without bevacizumab (Bev) is a standard therapy for platinum-resistant ovarian cancer (PR-OC). However, there is a lack of literature on chemotherapy agent selection in heterogenous PR-OC. Therefore, we aimed to clarify the heterogeneous treatment effects of each chemotherapy agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who underwent single-drug chemotherapy agents or Bev combination therapy for PR-OC between January 2009 and June 2022 were included in this study. We assessed the impact of each chemotherapy agent on the time to treatment failure (TTF) according to histological type, platinum-free interval (PFI), and Bev usage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 158 patients received 343 different chemotherapy regimens. In patients with clear cell carcinoma\/mucinous carcinoma (CC\/MC), gemcitabine (GEM) had the strongest effect with a median TTF of 5.3\u00a0months, whilst nedaplatin (NDP) had the lowest effect with a median TTF of 1.4\u00a0months. In contrast, in the non-CC\/MC group, irinotecan (CPT-11) and NDP had a better TTF than GEM and pegylated liposomal doxorubicin (PLD). There were notable differences in the treatment efficacy of NDP according to PFI. Specifically, NDP prolonged the TTF in patients with a PFI\u2009\u2265\u20093\u00a0months. Compared with GEM alone, GEM\u2009+\u2009Bev tended to prolong the TTF more effectively; however, an additive effect was not observed with PLD\u2009+\u2009Bev.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated that the effect of chemotherapy agents differed according to the tumor and background characteristics of the patient. Our findings will improve selection of effective therapies for patients with PR-OC by considering their background characteristics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-023-02367-1","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T04:19:17Z","timestamp":1687407557000},"page":"1207-1217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer"],"prefix":"10.1007","volume":"28","author":[{"given":"Katsuhiko","family":"Nara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-3871","authenticated-orcid":false,"given":"Ayumi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konan","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Tojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harunori","family":"Honjoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenbun","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuyo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"2367_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"2367_CR2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e32","volume":"28","author":"W Yamagami","year":"2017","unstructured":"Yamagami W, Nagase S, Takahashi F et al (2017) Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 28:e32","journal-title":"J Gynecol Oncol"},{"key":"2367_CR3","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2021.32.e49","volume":"32","author":"H Tokunaga","year":"2021","unstructured":"Tokunaga H, Mikami M, Nagase S et al (2021) The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. J Gynecol Oncol 32:e49","journal-title":"J Gynecol Oncol"},{"key":"2367_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN et al (2021) Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19:191\u2013226","journal-title":"J Natl Compr Canc Netw"},{"key":"2367_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","volume":"100","author":"K Matsumoto","year":"2006","unstructured":"Matsumoto K, Katsumata N, Yamanaka Y et al (2006) The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 100:412\u2013416","journal-title":"Gynecol Oncol"},{"key":"2367_CR6","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818","journal-title":"J Clin Oncol"},{"key":"2367_CR7","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"2367_CR8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the Aurelia open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308","journal-title":"J Clin Oncol"},{"key":"2367_CR9","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","volume":"20","author":"M Markman","year":"2002","unstructured":"Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365\u20132369","journal-title":"J Clin Oncol"},{"key":"2367_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/cas.15185","volume":"113","author":"T Shoji","year":"2022","unstructured":"Shoji T, Enomoto T, Abe M et al (2022) Efficacy and safety of standard of care with\/without bevacizumab for platinum-resistant ovarian\/fallopian tube\/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023. Cancer Sci 113:240\u2013250","journal-title":"Cancer Sci"},{"key":"2367_CR11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","volume":"22","author":"V Hess","year":"2004","unstructured":"Hess V, A\u2019Hern R, Nasiri N et al (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22:1040\u20131044","journal-title":"J Clin Oncol"},{"key":"2367_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ygyno.2005.12.038","volume":"102","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Fountzilas G, Aravantinos G et al (2006) Advanced stage clear-cell epithelial ovarian cancer: the hellenic cooperative oncology group experience. Gynecol Oncol 102:285\u2013291","journal-title":"Gynecol Oncol"},{"key":"2367_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14:1020\u20131026","journal-title":"Lancet Oncol"},{"key":"2367_CR14","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 23:2605\u20132612","journal-title":"Ann Oncol"},{"key":"2367_CR15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/annonc\/mdw236","volume":"27","author":"F Trillsch","year":"2016","unstructured":"Trillsch F, Mahner S, Hilpert F et al (2016) Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Ann Oncol 27:1733\u20131739","journal-title":"Ann Oncol"},{"key":"2367_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00432-020-03168-z","volume":"146","author":"MK Kato","year":"2020","unstructured":"Kato MK, Yunokawa M, Bun S et al (2020) Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data. J Cancer Res Clin Oncol 146:1335\u20131341","journal-title":"J Cancer Res Clin Oncol"},{"key":"2367_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00280-019-03834-1","volume":"84","author":"M Kobayashi-Kato","year":"2019","unstructured":"Kobayashi-Kato M, Yunokawa M, Bun S et al (2019) Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer. Cancer Chemother Pharmacol 84:33\u201339","journal-title":"Cancer Chemother Pharmacol"},{"key":"2367_CR18","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","volume":"33","author":"AM Poveda","year":"2015","unstructured":"Poveda AM, Selle F, Hilpert F et al (2015) Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J Clin Oncol 33:3836\u20133838","journal-title":"J Clin Oncol"},{"key":"2367_CR19","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.19.00194","volume":"37","author":"E Pujade-Lauraine","year":"2019","unstructured":"Pujade-Lauraine E, Banerjee S et al (2019) Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol 37:2437\u20132448","journal-title":"J Clin Oncol"},{"key":"2367_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ygyno.2019.10.002","volume":"155","author":"T Kuroda","year":"2019","unstructured":"Kuroda T, Ogiwara H, Sasaki M et al (2019) Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Gynecol Oncol 155:489\u2013498","journal-title":"Gynecol Oncol"},{"key":"2367_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000358730","volume":"86","author":"F Esposito","year":"2014","unstructured":"Esposito F, Cecere SC, Magazzino F et al (2014) Second-line chemotherapy in recurrent clear cell ovarian cancer: Results from the multicenter Italian trials in ovarian cancer (MITO-9). Oncology 86:351\u2013358","journal-title":"Oncology"},{"key":"2367_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000065715","volume":"63","author":"T Sugiyama","year":"2002","unstructured":"Sugiyama T, Yakushiji M, Kamura T et al (2002) Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. Oncology 63:16\u201322","journal-title":"Oncology"},{"key":"2367_CR23","first-page":"1301","volume":"16","author":"M Takano","year":"2006","unstructured":"Takano M, Kikuchi Y, Yaegashi N et al (2006) Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 16:1301\u20131306","journal-title":"Oncol Rep"},{"key":"2367_CR24","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","volume":"34","author":"T Sugiyama","year":"2016","unstructured":"Sugiyama T, Okamoto A, Enomoto T et al (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial. J Clin Oncol 34:2881\u20132887","journal-title":"J Clin Oncol"},{"key":"2367_CR25","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.21873\/anticanres.15964","volume":"42","author":"S Tatsuki","year":"2022","unstructured":"Tatsuki S, Shoji T, Abe M et al (2022) Efficacy and safety of platinum rechallenge in patients with platinum-resistant ovarian, Fallopian tube or primary peritoneal cancer: a multicenter retrospective study. Anticancer Res 42:4603\u20134610","journal-title":"Anticancer Res"},{"key":"2367_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1447-0756.2010.01217.x","volume":"36","author":"T Goto","year":"2010","unstructured":"Goto T, Takano M, Ohishi R et al (2010) Single nedaplatin treatment as salvage chemotherapy for platinum\/taxane-resistant\/refractory epithelial ovarian, tubal and peritoneal cancers. J Obstet Gynaecol Res 36:764\u2013768","journal-title":"J Obstet Gynaecol Res"},{"key":"2367_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131579","volume":"10","author":"L Mo","year":"2015","unstructured":"Mo L, Pospichalova V, Huang Z et al (2015) Ascites increases expression\/function of multidrug resistance proteins in ovarian cancer cells. PLoS ONE 10:e0131579","journal-title":"PLoS ONE"},{"key":"2367_CR28","doi-asserted-by":"publisher","first-page":"11913","DOI":"10.1038\/s41598-020-68639-2","volume":"10","author":"M Asem","year":"2020","unstructured":"Asem M, Young A, Oyama C et al (2020) Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer. Sci Rep 10:11913","journal-title":"Sci Rep"},{"key":"2367_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/jjco\/hyt040","volume":"43","author":"T Shiozawa","year":"2013","unstructured":"Shiozawa T, Tadokoro J, Fujiki T et al (2013) Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 43:483\u2013491","journal-title":"Jpn J Clin Oncol"},{"key":"2367_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2018.10.031","volume":"152","author":"JY Lee","year":"2019","unstructured":"Lee JY, Park JY, Park SY et al (2019) Real-world effectiveness of bevacizumab based on Aurelia in platinum-resistant recurrent ovarian cancer (REBECA): a Korean Gynecologic Oncology Group study (KGOG 3041). Gynecol Oncol 152:61\u201367","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02367-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T21:02:32Z","timestamp":1693429352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02367-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2367"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02367-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2759326\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No author has any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}